AIM ImmunoTech Inc.
AIMI
$0.0807
$0.012718.68%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.77% | -23.91% | 19.05% | -18.37% | 16.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.77% | -23.91% | 19.05% | -18.37% | 16.07% |
| Cost of Revenue | -41.67% | -73.33% | -- | -- | -- |
| Gross Profit | -28.30% | 68.75% | 0.00% | -34.69% | -5.36% |
| SG&A Expenses | -60.59% | -43.39% | 1.61% | 69.45% | 194.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.06% | -44.85% | -31.96% | 32.92% | 150.69% |
| Operating Income | 58.19% | 44.97% | 32.36% | -33.50% | -152.05% |
| Income Before Tax | 52.55% | 52.66% | 62.60% | -58.89% | -186.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.55% | 52.66% | 62.60% | -58.89% | -186.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.55% | 52.66% | 62.60% | -58.89% | -186.53% |
| EBIT | 58.19% | 44.97% | 32.36% | -33.50% | -152.05% |
| EBITDA | 58.48% | 45.38% | 32.48% | -33.62% | -158.93% |
| EPS Basic | 63.76% | 60.05% | 65.78% | -55.56% | -181.71% |
| Normalized Basic EPS | 66.00% | 55.57% | 66.72% | -45.77% | -184.56% |
| EPS Diluted | 63.76% | 60.05% | 65.78% | -50.00% | -181.71% |
| Normalized Diluted EPS | 66.00% | 55.57% | 66.72% | -45.77% | -184.56% |
| Average Basic Shares Outstanding | 30.93% | 18.59% | 9.14% | 2.19% | 1.69% |
| Average Diluted Shares Outstanding | 30.93% | 18.59% | 9.14% | 2.19% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |